Sharp Therapeutics Ratios and Metrics

Market cap in millions CAD. Fiscal year is January - December.

Millions CAD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022
Period Ending	Feb '26 Feb 17, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Market Capitalization	68	30	-	-
Enterprise Value	67	50	-	-
Last Close Price	2.25	1.05	1.05	-
PB Ratio	34.32	7.97	-	-
P/TBV Ratio	34.32	7.97	-	-
Debt / Equity Ratio	0.91	0.51	-1.10	-1.15
Net Debt / Equity Ratio	-0.49	-0.84	-1.06	-1.13
Net Debt / EBITDA Ratio	0.18	0.86	-5.46	-3.78
Net Debt / FCF Ratio	0.13	0.60	-6.20	-4.36
Quick Ratio	4.62	5.05	0.05	0.04
Current Ratio	4.80	5.10	0.06	0.05
Return on Assets (ROA)	-	-52.06%	-95.55%	-
Return on Capital Employed (ROCE)	-150.50%	-65.80%	36.70%	86.80%
Earnings Yield	-6.85%	-15.83%	-	-
FCF Yield	-	-17.63%	-	-
Buyback Yield / Dilution	-1300.62%	-107.12%	-3028.62%	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.